Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE.

Oncotarget. 2015 Jul 10;6(19):17314-27.

2.

Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.

Needham LA, Davidson AH, Bawden LJ, Belfield A, Bone EA, Brotherton DH, Bryant S, Charlton MH, Clark VL, Davies SJ, Donald A, Day FA, Krige D, Legris V, McDermott J, McGovern Y, Owen J, Patel SR, Pintat S, Testar RJ, Wells GM, Moffat D, Drummond AH.

J Pharmacol Exp Ther. 2011 Oct;339(1):132-42. doi: 10.1124/jpet.111.183640. Epub 2011 Jul 21.

PMID:
21778281
3.

Aminopeptidase inhibition as a targeted treatment strategy in myeloma.

Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE.

Mol Cancer Ther. 2009 Apr;8(4):762-70. doi: 10.1158/1535-7163.MCT-08-0735.

4.

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.

Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH.

Cancer Res. 2008 Aug 15;68(16):6669-79. doi: 10.1158/0008-5472.CAN-07-6627.

5.

The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.

Martin FM, Beckett RP, Bellamy CL, Courtney PF, Davies SJ, Drummond AH, Dodd R, Pratt LM, Patel SR, Ricketts ML, Todd RS, Tuffnell AR, Ward JW, Whittaker M.

Bioorg Med Chem Lett. 1999 Oct 4;9(19):2887-92.

PMID:
10522712
6.

Involvement of matrix metalloproteinases in human immunodeficiency virus type 1-induced replication by clinical Mycobacterium avium isolates.

Dezzutti CS, Swords WE, Guenthner PC, Sasso DR, Wahl LM, Drummond AH, Newman GW, King CH, Quinn FD, Lal RB.

J Infect Dis. 1999 Oct;180(4):1142-52.

PMID:
10479141
7.

Preclinical and clinical studies of MMP inhibitors in cancer.

Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A.

Ann N Y Acad Sci. 1999 Jun 30;878:228-35. Review.

PMID:
10415734
8.

The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.

Pratt LM, Beckett RP, Bellamy CL, Corkill DJ, Cossins J, Courtney PF, Davies SJ, Davidson AH, Drummond AH, Helfrich K, Lewis CN, Mangan M, Martin FM, Miller K, Nayee P, Ricketts ML, Thomas W, Todd RS, Whittaker M.

Bioorg Med Chem Lett. 1998 Jun 2;8(11):1359-64.

PMID:
9871766
9.

Role of metalloproteases in the release of the IL-1 type II decoy receptor.

Orlando S, Sironi M, Bianchi G, Drummond AH, Boraschi D, Yabes D, Mantovani A.

J Biol Chem. 1997 Dec 12;272(50):31764-9.

10.

Fas ligand in human serum.

Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S.

Nat Med. 1996 Mar;2(3):317-22.

PMID:
8612231
11.

BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.

Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ.

Blood. 1995 Dec 15;86(12):4400-8.

PMID:
8541527
12.

Matrix metalloproteinases and processing of pro-TNF-alpha.

Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, et al.

J Leukoc Biol. 1995 May;57(5):774-7. Review.

PMID:
7759957
13.

Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al.

Nature. 1994 Aug 18;370(6490):555-7.

PMID:
8052310
14.

Pathways of dephosphorylation of 1-D-myo-inositol 1,4,5-trisphosphate in GH3 pituitary tumor cells.

Ruiz-Larrea F, Drummond AH.

Biochim Biophys Acta. 1993 Jul 28;1178(1):63-72.

PMID:
8392378
15.

Metalloproteinase inhibitors as therapeutics.

Gordon JL, Drummond AH, Galloway WA.

Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S91-4. Review.

PMID:
8391953
16.

Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells.

Varney MA, Godfrey PP, Drummond AH, Watson SP.

Mol Pharmacol. 1992 Oct;42(4):671-8.

PMID:
1435742
17.

Purification and analysis of proteinase-resistant mutants of recombinant platelet-derived growth factor-BB exhibiting improved biological activity.

Cook AL, Kirwin PM, Craig S, Bawden LJ, Green DR, Price MJ, Richardson SJ, Fallon A, Drummond AH, Edwards RM, et al.

Biochem J. 1992 Jan 1;281 ( Pt 1):57-65.

18.

Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation.

Clements JM, Bawden LJ, Bloxidge RE, Catlin G, Cook AL, Craig S, Drummond AH, Edwards RM, Fallon A, Green DR, et al.

EMBO J. 1991 Dec;10(13):4113-20.

19.
20.

Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.

Drummond AH, Hughes PJ, Ruiz-Larrea F, Joels LA.

Ann N Y Acad Sci. 1989;553:197-204. Review. No abstract available.

PMID:
2566295
21.

Lithium affects G-protein receptor coupling.

Drummond AH.

Nature. 1988 Feb 4;331(6155):388. No abstract available.

PMID:
3123995
23.

The interaction of lithium ions with inositol lipid signalling systems.

Drummond AH, Joels LA, Hughes PJ.

Biochem Soc Trans. 1987 Feb;15(1):32-5. No abstract available.

PMID:
3104110
24.
25.
26.
27.

The role of inositol lipids in hormonal mobilization of cell-associated Ca2+.

Drummond AH, Knox RJ, Macphee CH.

Biochem Soc Trans. 1985 Feb;13(1):58-60. No abstract available.

PMID:
2987061
28.
29.

Control of animal cell proliferation by prostaglandin F2 alpha and other hormones: multisignal hypothesis for control of cell division.

Jimenez de Asua L, Otto AM, Drummond AH, Macphee CH, Smith C.

Adv Prostaglandin Thromboxane Leukot Res. 1985;15:391-3. No abstract available.

PMID:
2936129
32.
33.

Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle.

Bowman A, Drummond AH.

Br J Pharmacol. 1984 Apr;81(4):665-74.

34.

Thyrotropin-releasing hormone-stimulated [3H]inositol metabolism in GH3 pituitary tumor cells. Studies with lithium.

Drummond AH, Bushfield M, Macphee CH.

Mol Pharmacol. 1984 Mar;25(2):201-8.

PMID:
6321943
37.

Specific 5-hydroxytryptamine binding to rat platelets as a system to evaluate tricyclic antidepressants in plasma.

Carmen de Felipe M, Fuentes JA, Drummond AH.

Biochem Pharmacol. 1982 Apr 15;31(8):1661-3. No abstract available.

PMID:
7092958
38.
39.

Serotonin-induced hyperpolarization of an indentified Aplysia neuron is mediated by cyclic AMP.

Drummond AH, Benson JA, Levitan IB.

Proc Natl Acad Sci U S A. 1980 Aug;77(8):5013-7.

40.

d-[3H]Lysergic acid diethylamide binding to serotonin receptors in the molluscan nervous system.

Drummond AH, Bucher F, Levitan IB.

J Biol Chem. 1980 Jul 25;255(14):6679-86.

41.
42.

Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy.

Norman JA, Drummond AH, Moser P.

Mol Pharmacol. 1979 Nov;16(3):1089-94. No abstract available.

PMID:
93689
43.

LSD labels a novel dopamine receptor in molluscan nervous system.

Drummond AH, Bucher F, Levitan IB.

Nature. 1978 Mar 23;272(5651):368-70. No abstract available.

PMID:
24805
44.

Abnormal platelet function in pre-eclampsia.

Whigham KA, Howie PW, Drummond AH, Prentice CR.

Br J Obstet Gynaecol. 1978 Jan;85(1):28-32.

PMID:
623722
45.
46.

Aspirin at therapeutic concentrations does not affect 5-hydroxytryptamine uptake by platelets.

Drummond AH, MacIntyre DE, Olverman HJ.

Br J Pharmacol. 1977 Apr;59(4):661-2.

47.

Effect of thio reagents on platelet transport processes and responses to stimuli.

MacIntyre DE, Grainge CA, Drummond AH, Gordon JL.

Biochem Pharmacol. 1977 Feb 15;26(4):319-23. No abstract available.

PMID:
849322
48.

A method for the removal of platelet aggregating activity of commercial apyrase.

Whigham KA, Drummond AH, Edgar W, Prentice CR.

Thromb Haemost. 1976 Dec 31;36(3):652-3. No abstract available.

PMID:
190728
50.

Supplemental Content

Loading ...
Support Center